Literature DB >> 24217545

Peptide receptor radionuclide therapy with (177)Lu DOTATATE in a case of recurrent carotid body paraganglioma with spinal metastases.

Santosh Kumar Gupta1, Suhas Singla, Sellam Karunanithi, Nishikant Damle, Chandrasekhar Bal.   

Abstract

Paragangliomas are rare benign neuroendocrine tumors, and 80% of all paragangliomas are either carotid body tumors or glomus jugulare tumors. We present a case of recurrent unresectable carotid body paraganglioma with nodal and T7 vertebral metastases in a 30-year-old man 6 years postsurgery detected with Ga DOTANOC PET/CT and was administered with peptide receptor radionuclide therapy using Lu DOTATATE. After 5 cycles of Lu DOTATATE (total cumulative activity of 750 mCi [27 GBq]), significant response at the primary site on Ga DOTANOC PET/CT and complete disappearance of nodal and T7 vertebral metastases were noted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24217545     DOI: 10.1097/RLU.0000000000000273

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols.

Authors:  William Makis; Karey McCann; Alexander J B McEwan
Journal:  Nucl Med Mol Imaging       Date:  2015-04-09

2.  Ga-68 DOTA-NOC PET/CT for the Detection of Residual/Recurrence in a Rare Case of Sacral Spinal Canal Paraganglioma.

Authors:  Tarun Kumar Jain; Rajender Kumar Basher; Jaya Shukla; Anish Bhattacharya; Mahesh Prakash; Bhagwant Rai Mittal
Journal:  World J Nucl Med       Date:  2016 Jan-Apr

Review 3.  Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

Authors:  David Taïeb; Abhishek Jha; Giorgio Treglia; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.